Targeting macrophages: therapeutic approaches in cancer

Nature Reviews Drug Discovery, Journal Year: 2018, Volume and Issue: 17(12), P. 887 - 904

Published: Oct. 26, 2018

Language: Английский

---

Hypoxic control of metastasis

Science, Journal Year: 2016, Volume and Issue: 352(6282), P. 175 - 180

Published: April 7, 2016

Metastatic disease is the leading cause of cancer-related deaths and involves critical interactions between tumor cells microenvironment. Hypoxia a potent microenvironmental factor promoting metastatic progression. Clinically, hypoxia expression hypoxia-inducible transcription factors HIF-1 HIF-2 are associated with increased distant metastasis poor survival in variety types. Moreover, HIF signaling malignant influences multiple steps within cascade. Here we review research focused on elucidating mechanisms by which hypoxic microenvironment promotes These studies have identified potential biomarkers therapeutic targets regulated that could be incorporated into strategies aimed at preventing treating disease.

Language: Английский

---

Therapeutic Targeting of the Tumor Microenvironment

Cancer Discovery, Journal Year: 2021, Volume and Issue: 11(4), P. 933 - 959

Published: April 1, 2021

Abstract Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a promising approach for cancer treatment in recent years due critical roles of TME regulating progression and modulating response standard-of-care therapies. Here, we summarize current knowledge regarding most advanced TME-directed therapies, which either been clinically approved or are currently being evaluated trials, including immunotherapies, antiangiogenic drugs, treatments directed against cancer-associated fibroblasts extracellular matrix. We also discuss some challenges associated with future perspectives this evolving field. Significance: This review provides comprehensive analysis therapies targeting TME, combining discussion underlying basic biology clinical evaluation different therapeutic approaches, highlighting perspectives.

Language: Английский

---

Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m ⁶ A-demethylation of NANOG mRNA

Proceedings of the National Academy of Sciences, Journal Year: 2016, Volume and Issue: 113(14)

Published: March 21, 2016

Significance Pluripotency factors, such as NANOG, play a critical role in the maintenance and specification of cancer stem cells, which are required for primary tumor formation metastasis. In this study, we report that exposure breast cells to hypoxia (i.e., reduced O 2 availability), is feature microenvironment, induces N 6 -methyladenosine (m A) demethylation stabilization NANOG mRNA, thereby promoting cell (BCSC) phenotype. We show inhibiting expression AlkB homolog 5 (ALKBH5), demethylates m A, or hypoxia-inducible factors (HIFs) HIF-1α HIF-2α, activate ALKBH5 gene transcription hypoxic an effective strategy decrease target BCSCs vivo.

Language: Английский

---

Hypoxia-Inducible Factors: Master Regulators of Cancer Progression

Trends in cancer, Journal Year: 2016, Volume and Issue: 2(12), P. 758 - 770

Published: Nov. 17, 2016

Language: Английский

---

Phagocytosis checkpoints as new targets for cancer immunotherapy

Nature reviews. Cancer, Journal Year: 2019, Volume and Issue: 19(10), P. 568 - 586

Published: Aug. 28, 2019

Language: Английский

---

The Role of HIF in Immunity and Inflammation

Cell Metabolism, Journal Year: 2020, Volume and Issue: 32(4), P. 524 - 536

Published: Aug. 26, 2020

Language: Английский

---

Cancer Stem Cells: The Architects of the Tumor Ecosystem

Cell stem cell, Journal Year: 2019, Volume and Issue: 24(1), P. 41 - 53

Published: Jan. 1, 2019

Language: Английский

---

The CD47-SIRPα Immune Checkpoint

Immunity, Journal Year: 2020, Volume and Issue: 52(5), P. 742 - 752

Published: May 1, 2020

Language: Английский

---

The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer

Immunological Reviews, Journal Year: 2017, Volume and Issue: 276(1), P. 145 - 164

Published: March 1, 2017

Summary Immune checkpoint inhibitors, including those targeting CTLA ‐4/B7 and the PD ‐1/ ‐L1 inhibitory pathways, are now available for clinical use in cancer patients, with other interesting inhibitors being currently development. Most of these have purpose to promote adaptive T cell‐mediated immunity against cancer. Here, we review another acting potentiate activity innate immune cells towards This is composed what has become known as ‘don't‐eat me’ signal CD 47, which a protein broadly expressed on normal often overexpressed cells, its counter‐receptor, myeloid immunoreceptor SIRP α. Blocking 47‐ α interactions been shown destruction by phagocytes, macrophages neutrophils. Furthermore, there growing evidence that axis may also antigen‐presenting cell function thereby stimulate anti‐cancer immunity. The development potential side effects discussed. Collectively, this identifies promising cancer, data first studies expected within coming years, an exciting rapidly developing field.

Language: Английский

---